GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.

IF 9.6 1区医学 Q1 MEDICINE, GENERAL & INTERNAL EClinicalMedicine Pub Date : 2024-08-30 eCollection Date: 2024-09-01 DOI:10.1016/j.eclinm.2024.102782

Nasreen Alfaris, Stephanie Waldrop, Veronica Johnson, Brunna Boaventura, Karla Kendrick, Fatima Cody Stanford

{"title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review.","authors":"Nasreen Alfaris, Stephanie Waldrop, Veronica Johnson, Brunna Boaventura, Karla Kendrick, Fatima Cody Stanford","doi":"10.1016/j.eclinm.2024.102782","DOIUrl":null,"url":null,"abstract":"Obesity and type 2 diabetes mellitus (T2DM) present major global health challenges, with an increasing prevalence worldwide. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a pivotal treatment option for both conditions, demonstrating efficacy in blood glucose management, weight reduction, cardiovascular disease prevention, and kidney health improvement. GLP-1, an incretin hormone, plays a crucial role in glucose metabolism and appetite regulation, influencing insulin secretion, insulin sensitivity, and gastric emptying. The therapeutic use of GLP-1RAs has evolved significantly, offering various formulations that provide different efficacy, routes of administration, and flexibility in dosing. These agents reduce HbA1c levels, facilitate weight loss, and exhibit cardiovascular protective effects, making them an integral component of T2DM and obesity management. This review will discuss the currently approved medication for T2DM and obesity, and will also highlight the advent of novel agents which are dual and triple hormonal agonists which represent the future direction of incretin-based therapy.Funding: National Institutes of HealthNIDDKU24 DK132733 (FCS), UE5 DK137285 (FCS), and P30 DK040561 (FCS).","PeriodicalId":11393,"journal":{"name":"EClinicalMedicine","volume":"75 ","pages":"102782"},"PeriodicalIF":9.6000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11402415/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"EClinicalMedicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.eclinm.2024.102782","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Obesity and type 2 diabetes mellitus (T2DM) present major global health challenges, with an increasing prevalence worldwide. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a pivotal treatment option for both conditions, demonstrating efficacy in blood glucose management, weight reduction, cardiovascular disease prevention, and kidney health improvement. GLP-1, an incretin hormone, plays a crucial role in glucose metabolism and appetite regulation, influencing insulin secretion, insulin sensitivity, and gastric emptying. The therapeutic use of GLP-1RAs has evolved significantly, offering various formulations that provide different efficacy, routes of administration, and flexibility in dosing. These agents reduce HbA1c levels, facilitate weight loss, and exhibit cardiovascular protective effects, making them an integral component of T2DM and obesity management. This review will discuss the currently approved medication for T2DM and obesity, and will also highlight the advent of novel agents which are dual and triple hormonal agonists which represent the future direction of incretin-based therapy.

Funding: National Institutes of HealthNIDDKU24 DK132733 (FCS), UE5 DK137285 (FCS), and P30 DK040561 (FCS).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用于治疗 2 型糖尿病和肥胖症的 GLP-1 单一、双重和三重受体激动剂：综述。

肥胖症和 2 型糖尿病（T2DM）是全球健康面临的重大挑战，在全球的发病率不断上升。胰高血糖素样肽-1 受体激动剂（GLP-1RAs）已成为治疗这两种疾病的关键药物，在控制血糖、减轻体重、预防心血管疾病和改善肾脏健康方面具有显著疗效。GLP-1 是一种增量素激素，在葡萄糖代谢和食欲调节中起着至关重要的作用，影响着胰岛素分泌、胰岛素敏感性和胃排空。GLP-1RA 的治疗用途有了长足的发展，提供了具有不同疗效、给药途径和剂量灵活性的各种制剂。这些药物可降低 HbA1c 水平，促进体重减轻，并具有保护心血管的作用，是治疗 T2DM 和肥胖症不可或缺的药物。本综述将讨论目前已获批准的治疗 T2DM 和肥胖症的药物，还将重点介绍新型药物的出现，这些药物是双重和三重激素激动剂，代表了基于增量素疗法的未来方向：美国国立卫生研究院NIDDKU24 DK132733（FCS）、UE5 DK137285（FCS）和P30 DK040561（FCS）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

EClinicalMedicine Medicine-Medicine (all)

CiteScore

18.90

自引率

1.30%

发文量

506

审稿时长

22 days

期刊介绍： eClinicalMedicine is a gold open-access clinical journal designed to support frontline health professionals in addressing the complex and rapid health transitions affecting societies globally. The journal aims to assist practitioners in overcoming healthcare challenges across diverse communities, spanning diagnosis, treatment, prevention, and health promotion. Integrating disciplines from various specialties and life stages, it seeks to enhance health systems as fundamental institutions within societies. With a forward-thinking approach, eClinicalMedicine aims to redefine the future of healthcare.